EphB4 provides survival advantage to squamous cell carcinoma of the head and neck. - Wikidata - wikimedia - TriplyDB

EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.

EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.

http://www.wikidata.org/entity/Q40292503

about

Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesis The Role of PTEN in Tumor Angiogenesis Tumor bioengineering using a transglutaminase crosslinked hydrogel Long term survival following the detection of circulating tumour cells in head and neck squamous cell carcinoma.PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma.Soluble EphB4 inhibition of PDGF-induced RPE migration in vitro.Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth.The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder EphB4 as a therapeutic target in mesothelioma Recent advances in biomarkers and potential targeted therapies in head and neck squamous cell carcinoma.Targeting the EphB4 receptor for cancer diagnosis and therapy monitoring.The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome.EphB4-targeted imaging with antibody h131, h131-F(ab')2 and h131-Fab.Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas.Membrane-mediated regulation of vascular identity.Inhibiting Eph kinase activity may not be "Eph"ective for cancer treatment.KSR1 and EPHB4 Regulate Myc and PGC1β To Promote Survival of Human Colon Tumors.The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand.Ephrin-independent regulation of cell substrate adhesion by the EphB4 receptor.EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma.Design, synthesis and characterization of novel small molecular inhibitors of ephrin-B2 binding to EphB4.Anti-tumour effects of antibodies targeting the extracellular cysteine-rich region of the receptor tyrosine kinase EphB4.The intrinsically kinase-inactive EPHB6 receptor predisposes cancer cells to DR5-induced apoptosis by promoting mitochondrial fragmentation.Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.Increased radiation sensitivity of head and neck squamous cell carcinoma with sphingosine kinase 1 inhibition.Overexpression of EphB4, EphrinB2, and epidermal growth factor receptor in papillary thyroid carcinoma: A pilot study.Expression of EphrinB2 and EphB4 in glioma tissues correlated to the progression of glioma and the prognosis of glioblastoma patients.Humanized anti-EphB4 antibodies for the treatment of carcinomas and vasculogenesis-related diseases.Ephrin-B2 reverse signaling regulates progression and lymph node metastasis of oral squamous cell carcinoma.EphB4: A promising target for upper aerodigestive malignancies.

P2860

Q21328694-CE603D36-23E3-4E2A-BAC8-DD8F49FD97A6 Q28391620-766EE7A5-CD20-4515-AA8E-DC2B5DE35335 Q28542066-CAC0FE2D-FC0E-49A7-9B19-026EA0B135E1 Q30955321-06BA3261-0D98-49B1-99BE-297E3BFE8601 Q33674238-D0FF946B-FA9C-4AC5-B2EF-515E2DCBC155 Q33687354-21273E20-9604-4601-AEA1-1B703DF9906F Q33745300-955A241B-30CE-45B5-B2C0-1D446D4F9AFA Q34078717-A9411258-C35B-41BE-9552-D3AFB0F70986 Q34747922-92DB8CBA-997E-43D5-82FB-133DF1EC68C0 Q35825299-86E5E2FC-15A1-4CFE-B736-1028B083894B Q36518309-D9A834B0-ED92-4DF9-A031-C7178BA1286A Q36610209-8FDB0248-9595-4B44-B86E-04F2D92DC5AA Q37466344-3E6B5556-FC04-4925-9A22-FD7A40309EDE Q37493010-65CEDA89-F1E5-4D3B-A6B5-056AD28FA0BF Q37643632-F9FBE788-D64B-4E3F-89AC-AAC335A9BD31 Q38270107-622CCBC3-A002-4403-BB83-822EFA3A00D4 Q38765961-058842BA-396C-4642-9D57-702FA88E29B3 Q39127472-9EFB065A-230D-4F80-9BAB-1B88BE5EC6EE Q39429505-FEE64A2A-A70B-48AD-9822-23F6EC648228 Q39833824-14B60154-947E-4A1B-8E18-939B7862AECD Q40079597-2152EB57-E952-489F-A270-4950E8C12E1E Q41821364-3841C366-4A13-4302-8AC6-6ECDFBEDBFA8 Q41828383-1E7A7271-D6D7-44F8-81F1-680895BE5A1C Q42314590-BD8BA016-A68B-4614-8C5E-0AA71D8F652E Q43083986-8FC8AE36-1FEE-4B0F-A533-A62329E433B6 Q44697049-83FBAB9F-8407-4B2A-AF30-09D493758165 Q45232514-7017BFFE-22DB-4218-B770-249773F60DA7 Q45548546-3D0A790A-D0A8-498C-8DBC-867A97F4D7E0 Q45954932-94EB2DD3-6D4D-4568-9D6B-A77BF4064FCE Q47120401-DE001BF3-6F34-454A-A8A4-65B1545512A2 Q49709391-A33ACE07-3B80-417E-BE79-5BEE8F270D0A

P2860

EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.

http://www.wikidata.org/entity/Q40292503

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.

@en

type

label

EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.

@en

prefLabel

EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.

@en

P1433

Q40292503-15A89C0C-FC13-4A07-8E83-5F340D47D359

P1476

Q40292503-77870594-FC18-4A58-9A08-5158A63A1173

P2093

Q40292503-3FB2F753-BCA1-458B-B595-9AD2FDEB308C

Q40292503-49B36A9B-0329-4AFB-8E3D-CDF18FF9C5C0

Q40292503-5451B619-91B1-4776-B22C-2B940B990260

Q40292503-5981BFC5-CE63-4C03-AA20-C250BA61D607

Q40292503-5999CE96-1440-4D84-AA9B-CA1F04F847AE

Q40292503-6BB9B5B8-50F7-417C-9A65-DCC083685430

Q40292503-75A05434-AF91-4D05-96B5-5035D07DEACA

Q40292503-962DCB32-0294-493A-A387-389915F50117

Q40292503-A997D793-DF5A-4064-BCBD-9DE0C58EDDCF

Q40292503-AFD3E6F9-7DD7-43F0-8A70-DE0764AE1CA1

P2860

Q40292503-7BBDA89B-1A1B-466A-A6C2-C3CF9DD8E6DF

Q40292503-7D63ABA4-BFE2-46B1-A13B-95A0620D894A

P304

Q40292503-DCAE6267-83E7-4142-BB21-927130A78F47

P31

Q40292503-B4799B3C-A46A-4097-A2DF-E43E738D2FA2

P356

Q40292503-6DEC5B35-83B9-4EEB-B849-E70884A9B591

P433

Q40292503-F1A9AA49-407C-4D47-9F06-45DA8C15E431

P478

Q40292503-168CC720-526C-4ED4-B064-5CB8D0242AB5

P50

Q40292503-B9103536-333D-4D03-AC82-B67C77A4B43F

P577

Q40292503-8DE51055-D6FD-4186-85C1-57C0B06B8CF0

P5875

Q40292503-E44A98CD-D004-4573-99B8-17ACFAD78B90

P698

Q40292503-24280640-16BF-4C6E-BD90-AA9E1BFB86D6

P356

P1433

International Journal of Cancer

P1476

EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.

@en

P2093

Axel H Schönthal

http://www.w3.org/2001/XMLSchema#string

Daniel Broek

http://www.w3.org/2001/XMLSchema#string

David L Crowe

http://www.w3.org/2001/XMLSchema#string

Guangbin Xia

http://www.w3.org/2001/XMLSchema#string

Jasbir Singh

http://www.w3.org/2001/XMLSchema#string

Parkash S Gill

http://www.w3.org/2001/XMLSchema#string

Ramachandra K Reddy

http://www.w3.org/2001/XMLSchema#string

Rizwan Masood

http://www.w3.org/2001/XMLSchema#string

S Ram Kumar

http://www.w3.org/2001/XMLSchema#string

Uttam K Sinha

http://www.w3.org/2001/XMLSchema#string

P2860

Gene amplification and overexpression of EGF receptor in squamous cell carcinomas of the head and neck.

Expression of receptor tyrosine kinase HTK (hepatoma transmembrane kinase) and HTK ligand by human leukemia-lymphoma cell lines.

P304

1236-1248

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.21926

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7165354

http://www.w3.org/2001/XMLSchema#string

P698

16615113

http://www.w3.org/2001/XMLSchema#string